PRNewswire

Ferrovial Completes Regulatory Review Process for Nasdaq Listing May 3, 2024 05:17PM

Listing marks intent to expand already-robust presence in North America

AMSTERDAM, May 3, 2024 /PRNewswire/ -- Ferrovial SE ("Ferrovial" or the "Company"), one of the world's leading infrastructure companies, has concluded the U.S. regulatory review process for the Company's registration statement filed with the U.S. Securities and Exchange Commission (the "SEC"), with the intention to directly list the Company's shares on Nasdaq Global Select Market ("Nasdaq").... (continue reading...)

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 3, 2024 05:15PM

NEW YORK, May 3, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of two individuals whose employment commenced in April 2024.  

... (continue reading...)

Vesica Health Announces Launch of AssureMDx Test to Improve Bladder Cancer Detection May 3, 2024 05:14PM

IRVINE, Calif., May 3, 2024 /PRNewswire/ -- VESICA HEALTH, INC., a leading multi-omics liquid biopsy company dedicated to improving the management of hematuria patients and the early detection of bladder cancer, today announced the launch of its laboratory-developed AssureMDx™ test.

Vesica Health Launches AssureMDx for Clinical testing

Christopher... (continue reading...)

Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals May 3, 2024 05:00PM

Sentynl, a Zydus Group company, receives worldwide proprietary rights to Zokinvy, adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases

Zokinvy is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients

SOLANA BEACH, Calif. and AHMEDABAD, India and PALO ALTO, Calif., May 3,... (continue reading...)

Spyre Therapeutics Announces Grants of Inducement Awards May 3, 2024 05:00PM

WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an... (continue reading...)